Pharvaris develops drug candidates for a rare and potentially life-threatening genetic condition called HAE and related indications. The company announced the pricing of its upsized initial public offering. The ordinary shares begin trading on the Nasdaq Global Select Market today.
Last November, Pharvaris has closed an oversubscribed $80 million Series C financing bringing its total venture funding to over $160 million to date. The company is now going public at Nasdaq. Prospects look promising. During the week the company was able to upsize its IPO. It was originally planned to offer 6.95 million shares at a proposed midpoint price of $18.00 per share. Today Pharvaris announced the pricing of its upsized initial public offering of 8,270,500 of its ordinary shares at an initial public offering price of $20.00 per share, for total gross proceeds of approximately $165.4 million. In addition, Pharvaris has granted the underwriters a 30-day over-allotment option to purchase up to an a